These clinical observations may be explained at a molecular level by the study of Scorza et al., who reported in a group of 12 SSc patients treated with Aminaphtone a significant reduction of ELAM-1 and VCAM-1 serum concentrations (see the dedicated section of this review for further details) [12]. This evidence concerns the gene VCAM1 and systemic sclerosis.